Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- MGB Biopharma Limited
- Target Recruit Count
- 34
- Registration Number
- NCT03824795
- Locations
- 🇨🇦
Foothills Medical Centre, Calgary, Alberta, Canada
🇺🇸Ochsner Clinic Foundation Infectious Disease Research, New Orleans, Louisiana, United States
🇺🇸Anne Arundel Medical Centre, Annapolis, Maryland, United States
Safety, Blood Levels and Effects of MGB-BP-3
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- MGB Biopharma Limited
- Target Recruit Count
- 40
- Registration Number
- NCT02518607
© Copyright 2025. All Rights Reserved by MedPath